All In Biotech

Drug Trial Radar · NCT04570839

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Jul 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Aug 31, 2020

Primary completion

May 15, 2024

Study completion May 15, 2024

Sponsor

Lead sponsor
Compugen LtdIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Sep 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM701 in combination with BMS-986207 and nivolumab in patients with advanced solid tumors.

Conditions

  • Endometrial Neoplasms
  • Ovarian Cancer
  • Solid Tumor
  • Head and Neck Cancer

Interventions

  • COM701 in combination with BMS-986207 and nivolumab.Drug

    Study treatment with the 3 drug combination (COM701 in combination with BMS-986207 and nivolumab).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of subjects with adverse events on the study.Time frame: 2 years.
  2. The proportion of subjects with adverse events in the 1st cycle during dose escalation within the DLT window (28 days).Time frame: Within the DLT window (1st 28 days) of the 1st cycle during dose escalation.
  3. The recommended dose for expansion (RDFE) of the combination.Time frame: 2 years.
  4. The Area under the curve of COM701 in subjects receiving the 3-drug combination.Time frame: 2 years.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Chicago Medical Center

    Chicago, Illinois

  • Johns Hopkins University Oncology Center.

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • START Midwest.

    Grand Rapids, Michigan

  • Columbia University

    New York, New York

  • University of Pittsburgh Cancer Center.

    Pittsburgh, Pennsylvania

  • The University of Tennessee WEST Cancer Center.

    Memphis, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • The START Center for Cancer Care.

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.